Policy | February 22, 2023
Mandaviya focuses on high value pharmaceuticals and high-end medical devices to reduce the import dependency
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
The Survey highlighted that Indian pharmaceutical exports achieved a healthy growth of 24 per cent in FY21 and expressed hope that India’s domestic pharmaceutical market is estimated to grow to US $65 billion by 2024 from estimated US $41 billion in 2021
Subscribe To Our Newsletter & Stay Updated
